These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16447039)

  • 1. Targeting cancer cells: magnetic nanoparticles as drug carriers.
    Alexiou C; Schmid RJ; Jurgons R; Kremer M; Wanner G; Bergemann C; Huenges E; Nawroth T; Arnold W; Parak FG
    Eur Biophys J; 2006 May; 35(5):446-50. PubMed ID: 16447039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.
    Alexiou C; Jurgons R; Schmid RJ; Bergemann C; Henke J; Erhardt W; Huenges E; Parak F
    J Drug Target; 2003 Apr; 11(3):139-49. PubMed ID: 13129824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Locoregional cancer treatment with magnetic drug targeting.
    Alexiou C; Arnold W; Klein RJ; Parak FG; Hulin P; Bergemann C; Erhardt W; Wagenpfeil S; Lübbe AS
    Cancer Res; 2000 Dec; 60(23):6641-8. PubMed ID: 11118047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Magnetic Drug Targeting--a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies].
    Alexiou C; Jurgons R; Schmid R; Erhardt W; Parak F; Bergemann C; Iro H
    HNO; 2005 Jul; 53(7):618-22. PubMed ID: 15549214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Magnetic drug targeting. New paths for the local concentration of drugs for head and neck cancer].
    Simon C
    HNO; 2005 Jul; 53(7):600-1. PubMed ID: 15868128
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on the adsorption and desorption of mitoxantrone to lauric acid/albumin coated iron oxide nanoparticles.
    Zaloga J; Feoktystov A; Garamus VM; Karawacka W; Ioffe A; Brückel T; Tietze R; Alexiou C; Lyer S
    Colloids Surf B Biointerfaces; 2018 Jan; 161():18-26. PubMed ID: 29035747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles.
    Dürr S; Lyer S; Mann J; Janko C; Tietze R; Schreiber E; Herrmann M; Alexiou C
    Anticancer Res; 2012 May; 32(5):1983-9. PubMed ID: 22593476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting to carcinoma cells with chitosan- and starch-coated magnetic nanoparticles for magnetic hyperthermia.
    Kim DH; Kim KN; Kim KM; Lee YK
    J Biomed Mater Res A; 2009 Jan; 88(1):1-11. PubMed ID: 18257079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles - a pilot study.
    Lyer S; Tietze R; Jurgons R; Struffert T; Engelhorn T; Schreiber E; Dörfler A; Alexiou C
    Anticancer Res; 2010 May; 30(5):1553-7. PubMed ID: 20592340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro analysis of cisplatin functionalized magnetic nanoparticles in combined cancer chemotherapy and electromagnetic hyperthermia.
    Babincov M; Altanerov V; Altaner C; Bergemann C; Babinec P
    IEEE Trans Nanobioscience; 2008 Mar; 7(1):15-9. PubMed ID: 18334449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of magnetic nanoparticles by magnetorelaxometry and comparison to histology after magnetic drug targeting.
    Wiekhorst F; Seliger C; Jurgons R; Steinhoff U; Eberbeck D; Trahms L; Alexiou C
    J Nanosci Nanotechnol; 2006; 6(9-10):3222-5. PubMed ID: 17048540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone-loaded superparamagnetic iron oxide nanoparticles as drug carriers for cancer therapy: Uptake and toxicity in primary human tubular epithelial cells.
    Cicha I; Scheffler L; Ebenau A; Lyer S; Alexiou C; Goppelt-Struebe M
    Nanotoxicology; 2016; 10(5):557-66. PubMed ID: 26468004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting.
    Alexiou C; Jurgons R; Seliger C; Brunke O; Iro H; Odenbach S
    Anticancer Res; 2007; 27(4A):2019-22. PubMed ID: 17649815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexagonal prism nanocarriers for mitigated phagocytosis.
    Park K
    J Control Release; 2011 Aug; 154(1):1. PubMed ID: 21771619
    [No Abstract]   [Full Text] [Related]  

  • 15. Specific targeting of cancer cells by multifunctional mitoxantrone-conjugated magnetic nanoparticles.
    Heidari Majd M; Asgari D; Barar J; Valizadeh H; Kafil V; Coukos G; Omidi Y
    J Drug Target; 2013 May; 21(4):328-40. PubMed ID: 23293842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery.
    Kohler N; Sun C; Fichtenholtz A; Gunn J; Fang C; Zhang M
    Small; 2006 Jun; 2(6):785-92. PubMed ID: 17193123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanostructured lipid-carrageenan hybrid carriers (NLCCs) for controlled delivery of mitoxantrone hydrochloride to enhance anticancer activity bypassing the BCRP-mediated efflux.
    Ling G; Zhang T; Zhang P; Sun J; He Z
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1351-9. PubMed ID: 26754913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical formulation of HSA hybrid coated iron oxide nanoparticles for magnetic drug targeting.
    Zaloga J; Pöttler M; Leitinger G; Friedrich RP; Almer G; Lyer S; Baum E; Tietze R; Heimke-Brinck R; Mangge H; Dörje F; Lee G; Alexiou C
    Eur J Pharm Biopharm; 2016 Apr; 101():152-62. PubMed ID: 26854862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary study on MeO-PEG-PLGA-PEG-OMe nanoparticles as intravenous carriers.
    Duan Y; Xu J; Lin Y; Yu H; Gong T; Li Y; Zhang Z
    J Biomed Mater Res A; 2008 Nov; 87(2):515-23. PubMed ID: 18186066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment.
    Krukemeyer MG; Krenn V; Jakobs M; Wagner W
    J Surg Res; 2012 Jun; 175(1):35-43. PubMed ID: 21470623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.